The endogenous opioid system and drug addiction;Le système opioïde endogène et l'addiction aux drogues

Annales Pharmaceutiques Francaises

Volumn 68, Issue 1, 2010, Pages 3-11

  Maldonado, R ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Alcohol; Cannabinoid; Cocaine; Morphine; Naltrexone; Nicotine

Indexed keywords

CANNABINOID; ENDORPHIN; NICOTINE; OPIATE; OPIATE PEPTIDE; OPIATE RECEPTOR; PSYCHOSTIMULANT AGENT;

DOPAMINERGIC ACTIVITY; DRUG DEPENDENCE; HUMAN; LIMBIC SYSTEM; MESENCEPHALON; REVIEW;

ALCOHOLISM; AMPHETAMINE-RELATED DISORDERS; ANIMALS; COCAINE-RELATED DISORDERS; ENDORPHINS; HUMANS; MARIJUANA ABUSE; OPIOID-RELATED DISORDERS; REWARD; SUBSTANCE-RELATED DISORDERS; TOBACCO USE DISORDER;

EID: 76749102959     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2009.12.001     Document Type: Review

References (114)

1. Camí J., and Farré M. Drug addiction. N Engl Med 349 (2003) 975-986
2. Koob G.F., and Le Moal M. Neurobiology of addiction (2006), Elsevier, London
3. Koob G.F., and Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 278 (1997) 52-58
4. Di Chiara G., Bassareo V., Fenu S., De Luca M.A., Spina L., Cadoni C., et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 47 Suppl 1 (2004) 227-241
5. Volkow N.D., Fowler J.S., Wang G.J., Baler R., and Telang F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 56 (2009) 3-8
6. Pert C.B., and Snyder S.H. Opiate receptor: demonstration in nervous tissue. Science 179 (1973) 1011-1014
7. Simon E.J., Hiller J.M., and Edelman I. Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate. Proc Natl Acad Sci U S A 70 (1973) 1947-1949
8. Terenius L. Characteristics of the "receptor" for narcotic analgesics in synaptic plasma membrane fraction from rat brain. Acta Pharmacol Toxicol 33 (1973) 377-384
9. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., and Gilbert P.E. The effects of morphine - and nalorphine - like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197 (1976) 517-532
10. Evans C.J., Keith Jr. D.E., Morrison H., Magendzo K., and Edwards R.H. Cloning of a delta opioid receptor by functional expression. Science 258 (1992) 1952-1955
11. Kieffer B.L., Befort K., Gaveriaux-Ruff C., and Hirth C.G. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci U S A 89 (1992) 12048-12052
12. Law P.Y., Wong Y.H., and Loh H.H. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 40 (2000) 389-430
13. Mollereau C., Parmentier M., Mailleux P., Butour J.L., Moisand C., Chalon P., et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 341 (1994) 33-38
14. Zeilhofer H.U., and Calò G. Nociceptin/orphanin FQ and its receptor - potential targets for pain therapy?. J Pharmacol Exp Ther 306 (2003) 423-429
15. Goodman R.R., Snyder S.H., Kuhar M.J., and Young W.S. Differentiation of delta and mu opiate receptor localizations by light microscopie autoradiography. Proc Natl Acad Sci U S A 77 (1980) 6239-6243
16. Waksman G., Hamel E., Fournié-Zaluski M.C., and Roques B.P. Autoradiographic comparison of the distribution of the neutral endopeptidase "enkephalinase" and mu delta opioid receptors in the brain. Proc Natl Acade Sci U S A. (1986) 83_1523-27
17. Mansour A., Fox C.A., Akil H., and Watson S.J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 18 (1995) 22-29
18. Arvidsson U., Dado R.J., Riedl M., Lee J.H., Laww P.Y., Loh H., et al. Delta-opioid receptor immunoreactivity: distribution in brainstem and spinal cord, and relationship to biogenic amines and enkephalin. J Neurosci 15 (1995) 1215-1235
19. Arvidsson U., Riedl M., Chakrabarti S., Lee J.H., Nakano A.H., Dado R.J., et al. Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J Neurosci 15 (1995) 3328-3341
20. Mansour A., Burke S., Pablic R.J., Akil H., and Watson S.J. Immunohistochemical localization of the cloned kappal receptor in the rat CNS pituitary. Neuroscience 71 (1996) 671-690
21. Florin S., Leroux-Nicollet I., Meunier J.C., and Costentin J. Autoradiographic localization of [3H] nociceptin binding sites from telecephalic to mesencephalic regions of the mouse brain. Neurosci Lett 230 (1997) 33-36
22. Kieffer B.L., and Gavériaux-Ruff C. Exploring the opioid system by gene knock-out. Prog Neurobiol 66 (2002) 285-306
23. Meador-Woodruff J.H., Pellirito B., Vaudry H., Jegous S., Seidah N.G., Watson S.J., et al. Regional processing of the N-and C-terminal domains of proopiomelanocortin in monkey pituitary and brain. Neuropeptides 11 (1988) 111-118
24. Pittius CW, Kley N, Loeffler JP, Höllt V. Quantitation of proenkephalin A messenger RNA in bovine brain, pituitary and adrenal medulla: correlation between mRNA and peptides levels 1985. Exp. Brain Res.;4:1527-60.
25. Höllt V., Przewlocki R., Haarmann I., Almeida O.F., Kley N., Millan M.J., et al. Stress-induced alterations in the levels of mRNA coding for poopiomelanocortin and prolactin in rat pituitary. Neuroendocrinology 43 (1986) 227-282
26. Khachaturian H., Lewis M.E., Tsou K., and Watson S.J. Anatomy of the CNS opioid systems. Trends Neurosci 8 (1985) 111-119
27. Roth-Deri I., Green-Sadan I., and Yadid G. Beta-endorphin and drug-induced reward and reinforcement. Prog Neurobiol 86 (2008) 1-21
28. Roques B.P., Noble F., Daugé V., Fournié-Zaluski M.C., and Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45 (1993) 87-146
29. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532-535
30. Ikeda K., Watanabe M., Ichikawa T., Kobayashi T., Yano R., and Kumanishi T. Distribution of prepro-nociceptin/orphanin FQ mRNA and its receptor mRNA in developing and adult mouse central nervous systems. J Comp Neurol 339 (1998) 139-151
31. Akil H., Meng F., Devine D.P., and Watson S.J. Molecular and neuroanatomical properties of the endogenous opioid systems: implications for the treatment of opiate addiction. Semin Neurosci 9 (1997) 70-83
32. Zadina J.E., Hackler L., Ge L.J., and Kastin A.J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386 (1997) 499-502
33. Hirose N., Murakawa K., Takada K., Oi Y., Suzuki T., Nagase H., et al. Interactions among mu-and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens. Neuroscience 135 (2005) 213-225
34. Yoshida Y., Koide S., Hirose N., Takada K., Tomiyama K., and Koshikawa N. Fentanyl increases dopamine release in rat nucleus accumbens: involvement of mesolimbic muand delta-2-opioid receptors. Neuroscience 92 (1999) 1357-1365
35. Johnson S., and North R. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12 (1992) 483-488
36. Steffensen S.C., Stobbs S.H., Colago E.E., Lee R.S., Koob G.F., Gallegos R.A., et al. Contingent and noncontingent effects of heroin on mu-opioid receptor-containing ventral tegmental area GABA neurons. Exp Neurol 202 (2006) 139-151
37. Devine D.P., and Wise R.A. Self-administration of morphine, DAMGO, and DPDPE into the ventral tegmental area of rats. J Neurosci 14 (1994) 1978-1984
38. Shippenberg T.S., LeFevour A., and Chefer V.I. Targeting endogenous mu-and deltaopioid receptor systems for the treatment of drug addiction. CNS Neurol Disord Drug Targets 7 (2008) 442-453
39. Matthes H.W.D., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the m-opioid receptor gene. Nature 383 (1996) 819-823
40. Hutcheson D.M., Matthes H.W., Valjent E., Sánchez-Blázquez P., Rodríguez-Díaz M., Garzón J., et al. Lack of dependence and rewarding effects of deltorphin II in mu-opioid receptor-deficient mice. Eur J Neurosci 13 (2001) 153-161
41. Narita M., Funada M., and Suzuki T. Regulations of opioid dependence by opioid receptor types. Pharmacol Ther 89 (2001) 1-15
42. Hoffman A.F., and Lupica C.R. Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids. J Neurophysiol 85 (2001) 72-83
43. Devine D.P., Leone P., Pocock D., and Wise R.A. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J Pharmacol Exp Ther 266 (1993) 1236-1246
44. Duvauchelle C.L., Fleming S.M., and Kornetsky C. DAMGO and DPDPE facilitation of brain stimulation reward thresholds is blocked by the dopamine antagonist cisflupenthixol. Neuropharmacology 36 (1997) 1109-1114
45. Todtenkopf M.S., Marcus J.F., Portoghese P.S., and Carlezon. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology 172 (2004) 463-470
46. Mucha R.F., and Herz A. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology 86 (1985) 274-280
47. Simonin F., Valverde O., Smadja C., Slowe S., Kitchen I., Dierich A., et al. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 17 (1998) 886-897
48. Chefer V.I., Czyzyk T., Bolan E.A., Moron J., Pintar J.E., and Shippenberg T.S. Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J Neurosci 25 (2005) 5029-5037
49. Shippenberg T.S., Zapata A., and Chefer V.I. Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 116 (2007) 306-321
50. Chefer V.I., and Shippenberg T.S. Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knock-out mice. Neuropsychopharmacology 34 (2009) 887-898
51. Xie W.Y., He Y., Yang Y.R., Li Y.F., Kang K., and Xing B.M. Disruption of Cdk5-associated phosphorylation of residue threonine-161 of the delta-opioid receptor: impaired receptor function and attenuated morphine antinociceptive tolerance. J Neurosci 29 (2009) 355164
52. Maldonado R., Valverde O., and Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29 (2006) 225-232
53. Pickel V.M., Chan J., Kash T.L., Rodriguez J.J., and MacKie K. Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience 127 (2004) 101-112
54. Rodríguez J.J., Mackie K., and Pickel V.M. Ultrastructural localization of the CB1 cannabinoid receptor in mu opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 21 (2001) 823-833
55. Schoffelmeer A.N., Hogenboom F., Wardeh G., and De Vries T.J. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51 (2006) 773-781
56. Chen J.P., Paredes W., Li J., Smith D., Lowinson, and Gardner E. Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102 (1990) 156-162
57. Tanda G., Pontieri F.E., and Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu-1-opioid receptor mechanism. Science 276 (1997) 2048-2050
58. Caillé S., and Parsons L.H. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology 31 (2006) 804-813
59. Maldonado R., and Valverde O. Participation of the opioid system in cannabinoidinduced antinociception and emotional-like responses. Eur Neuropsychopharmacol 13 (2003) 401-410
60. Ghozland S., Matthes H.W., Simonin F., Filliol D., Kieffer B.L., and Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 22 (2002) 1146-1154
61. Castañé A., Robledo P., Matifas A., Kieffer B.L., and Maldonado R. Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knock-out mice. Eur J Neurosci 17 (2003) 155-159
62. Navarro M., Carrera M.R., Fratta W., Valverde O., Cossu G., Fattore L., et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21 (2001) 5344-5350
63. Justinova Z., Tanda G., Munzar P., and Goldberg S.R. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9-tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology 173 (2004) 186-194
64. Solinas M., and Goldberg S.R. Involvement of mu-, delta-and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats. Psychopharmacology 179 (2005) 804-812
65. Spano M.S., Fattore L., Cossu G., Deiana S., Fadda P., and Fratta W. CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. Br J Pharmacol 143 (2004) 343-350
66. Zimmer A., Valjent E., Konig M., Zimmer A.M., Robledo P., Hahn H., et al. Absence of delta-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. J Neurosci 21 (2001) 9499-9505
67. Cheng H.Y., Laviolette S.R., van der Kooy D., and Penninger J.M. Dream ablation selectively alters THC place aversion and analgesia but leaves intact the motivational and analgesic effects of morphine. Eur J Neurosci 19 (2004) 3033-3041
68. Mendizabal V., Zimmer A., and Maldonado R. Involvement of kappa/dynorphin system in WIN 55,212-2 self-administration in mice. Neuropsychopharmacology 31 (2006) 195766
69. Valverde O., Maldonado R., Valjent E., Zimmer A.M., and Zimmer A. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci 20 (2000) 9284-9289
70. Lichtman A.H., Sheikh S.M., Loh H.H., and Martin B.R. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphinedependent mice. J Pharmacol Exp Ther 298 (2001) 1007-1014
71. Tanda G., Munzar P., and Goldberg S.R. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 3 (2000) 1073-1074
72. Gerrits M.A., Patkina N., Zvartau E.E., and van Ree J.M. Opioid blockade attenuates acquisition and expression of cocaine-induced place preference conditioning in rats. Psychopharmacology 119 (1995) 92-98
73. Suzuki T., Shiozaki Y., Masukawa Y., Misawa M., and Nagase H. The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference. Jpn J Pharmacol 58 (1992) 435-442
74. Rademacher D.J., and Steinpreis R.E. Effects of the selective mu(1)-opioid receptor antagonist, naloxonazine, on cocaine-induced conditioned place preference and locomotor behavior in rats. Neurosci Lett 332 (2002) 159-162
75. Schroeder J.A., Hummel M., Simpson A.D., Sheikh R., Soderman A.R., and Unterwald E.M. A role for mu-opioid receptors in cocaine-induced activity, sensitization, and reward in the rat. Psychopharmacology 195 (2007) 265-272
76. Hummel M., Schroeder J., Liu-Chen L.Y., Cowan A., and Unterwald E.M. An antisense oligodeoxynucleotide to the mu-opioid receptor attenuates cocaine-induced behavioral sensitization and reward in mice. Neuroscience 142 (2006) 481-491
77. Corrigall W.A., and Coen K.M. Opiate antagonists reduce cocaine but not nicotine self-administration. Psychopharmacology 104 (1991) 167-170
78. Ramsey N.F., Gerrits M.A., and van Ree J.M. Naltrexone affects cocaine self-administration in naive rats through the ventral tegmental area rather than dopaminergic target regions. Eur Neuropsychopharmacol 9 (1999) 93-99
79. Mathon D.S., Lesscher H.M., Gerrits M.A., Kamal A., Pintar J.E., Schuller A.G., et al. Increased gabaergic input to ventral tegmental area dopaminergic neurons associated with decreased cocaine reinforcement in mu-opioid receptor knock-out mice. Neuroscience 130 (2005) 359-367
80. Corrigall W.A., Coen K.M., Adamson K.L., and Chow B.L. The mu opioid agonist DAMGO alters the intravenous self-administration of cocaine in rats: mechanisms in the ventral tegmental area. Psychopharmacology 141 (1999) 428-435
81. Menkens K., Bilsky E.J., Wild K.D., Portoghese P.S., Reid L.D., and Porreca F. Cocaine place preference is blocked by the delta-opioid receptor antagonist, naltrindole. Eur J Pharmacol 219 (1992) 345-346
82. Suzuki T., Mori T., Tsuji M., Misawa M., and Nagase H. The role of delta-opioid receptor subtypes in cocaine-and methamphetamine-induced place preferences. Life Sci 55 (1994) L339-L344
83. Reid L.D., Glick S.D., Menkens K.A., French E.D., Bilsky E.J., and Porreca F. Cocaine self-administration and naltrindole, a delta-selective opioid antagonist. Neuroreport 6 (1995) 1409-1412
84. de Vries T.J., Babovic-Vuksanovic D., Elmer G., and Shippenberg T.S. Lack of involvement of delta-opioid receptors in mediating the rewarding effects of cocaine. Psychopharmacology 120 (1995) 442-448
85. Ward S.J., and Roberts D.C. Microinjection of the delta-opioid receptor selective antagonist naltrindole 5′-isothiocyanate site specifically affects cocaine self-administration in rats responding under a progressive ratio schedule of reinforcement. Behav Brain Res 182 (2007) 140-144
86. Glick S.D., Maisonneuve I.M., Raucci J., and Archer S. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 681 (1995) 147-152
87. Tomasiewicz H.C., Todtenkopf M.S., Chartoff E.H., Cohen B.M., and Carlezon. The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry 64 (2008) 982-988
88. Kuzmin A.V., Gerrits M.A., and van Ree J.M. Kappa-opioid receptor blockade with norbinaltorphimine modulates cocaine self-administration in drug-naive rats. Eur J Pharmacol 358 (1998) 197-202
89. Acquas E., Meloni M., and Di Chiara G. Blockade of delta-opioid receptors in the nucleus accumbens prevents ethanol-induced stimulation of dopamine release. Eur J Pharmacol 230 (1993) 239-241
90. Job M.O., Tang A., Hall F.S., Sora I., Uhl G.R., Bergeson S.E., et al. Mu opioid receptor regulation of ethanol-induced dopamine response in the ventral striatum: evidence of genotype specific sexual dimorphic epistasis. Biol Psychiatry 62 (2007) 627-634
91. Lee Y.K., Park S.W., Kim Y.K., Kim D.J., Jeong J., Myrick H., et al. Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system. Alcohol 40 (2005) 297-301
92. Roberts A.J., McDonald J.S., Heyser C.J., Kieffer B.L., Matthes H.W., and Koob G.F. mu-Opioid receptor knock-out mice do not self-administer alcohol. J Pharmacol Exp Ther 293 (2000) 1002-1008
93. Roberts A.J., Gold L.H., Polis I., McDonald J.S., Filliol D., and Kieffer B.L. Increased ethanol self-administration in delta-opioid receptor knock-out mice. Alcohol Clin Exp Res 25 (2001) 1249-1256
94. Racz I., Schürmann B., Karpushova A., Reuter M., Cichon S., Montag C., et al. The opioid peptides enkephalin and beta-endorphin in alcohol dependence. Biol Psychiatry 64 (2008) 989-997
95. de Waele J.P., and Gianoulakis C. Characterization of the mu and delta opioid receptors in the brain of the C57BL/6 and DBA/2 mice, selected for their differences in voluntary ethanol consumption. Alcohol Clin Exp Res 21 (1997) 754-762
96. Soini S.L., Hyytiä P., and Korpi E.R. Brain regional mu-opioid receptor function in rat lines selected for differences in alcohol preference. Eur J Pharmacol 448 (2002) 157-163
97. Zhang H., Kranzler H.R., Weiss R.D., Luo X., Brady K.T., Anton R.F., et al. Proopiomelanocortin gene variation related to alcohol or drug dependence: Evidence and replications across family-and population-based studies. Biol Psychiatry 66 (2009) 128-136
98. Zhang H., Luo X., Kranzler H.R., Lappalainen J., Yang B.Z., Krupitsky E., et al. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet 15 (2006) 807-819
99. Xuei X., Dick D., Flury-Wetherill L., Tian H.J., Agrawal A., and Bierut L. Association of the kappa-opioid system with alcohol dependence. Mol Psychiatry 11 (2006) 1016-1024
100. Walker B.M., and Koob G.F. Pharmacological evidence for a motivational role of kappaopioid systems in ethanol dependence. Neuropsychopharmacology 33 (2008) 643-652
101. Balerio G.N., Aso E., and Maldonado R. Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology 181 (2005) 260-269
102. Trigo J.M., Zimmer A., and Maldonado R. Nicotine anxiogenic and rewarding effects are decreased in mice lacking beta-endorphin. Neuropharmacology 56 (2009) 1147-1153
103. Zarrindast M.R., Khoshayand M.R., and Shafaghi B. The development of cross-tolerance between morphine and nicotine in mice. Eur Neuropsychopharmacol 9 (1999) 227-233
104. Biala G., and Weglinska B. On the mechanism of cross-tolerance between morphineand nicotine-induced antinociception: involvement of calcium channels. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 15-21
105. Galeote L., Kieffer B.L., Maldonado R., and Berrendero F. Mu-opioid receptors are involved in the tolerance to nicotine antinociception. J Neurochem 97 (2006) 416-423
106. Rukstalis M., Jepson C., Strasser A., Lynch K.G., Perkins K., Patterson F., et al. Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology 180 (2005) 41-48
107. Berrendero F., Kieffer B.L., and Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J Neurosci 22 (2002) 10935-10940
108. Berrendero F., Mendizabal V., Robledo P., Galeote L., Bilkei-Gorzo A., Zimmer A., et al. Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. J Neurosci 25 (2005) 1103-1112
109. Galeote L., Maldonado R., and Berrendero F. Involvement of kappa/dynorphin system in the development of tolerance to nicotine-induced antinociception. J Neurochem 105 (2008) 1358-1368
110. Krishnan-Sarin S., Rosen M.I., and O'Malley S.S. Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Arch Gen Psychiatry 56 (1999) 663-668
111. Balerio G.N., Aso E., Berrendero F., Murtra P., and Maldonado R. Delta-9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur J Neurosci 20 (2004) 2737-2748
112. Watkins S.S., Stinus L., Koob G.F., and Markou A. Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther 292 (2000) 1053-1064
113. Ise Y., Narita M., Nagase H., and Suzuki T. Modulation of opioidergic system on mecamylamine-precipitated nicotine-withdrawal aversion in rats. Psychopharmacology 151 (2000) 49-54
114. Ise Y., Narita M., Nagase H., and Suzuki T. Modulation of kappa-opioidergic systems on mecamylamine-precipitated nicotine-withdrawal aversion in rats. Neurosci Lett 323 (2002) 164-166